FDA — authorised 30 July 1964
- Application: NDA014738
- Marketing authorisation holder: B BRAUN
- Local brand name: MANNITOL 20%
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Mannitol in United States
FDA authorised Mannitol on 30 July 1964
Marketing authorisations
FDA — authorised 8 October 1965
- Application: NDA016080
- Marketing authorisation holder: B BRAUN
- Local brand name: MANNITOL 20%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 22 December 1967
- Application: NDA016269
- Marketing authorisation holder: HOSPIRA
- Local brand name: MANNITOL 20%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
FDA
- Application: NDA016472
- Marketing authorisation holder: MILES
- Local brand name: MANNITOL 20%
- Indication: INJECTABLE — INJECTION
- Status: approved
Pricing & reimbursement
- annual_list: USD 0.00 per year
Mannitol in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Mannitol approved in United States?
Yes. FDA authorised it on 30 July 1964; FDA authorised it on 8 October 1965; FDA authorised it on 22 December 1967.
Who is the marketing authorisation holder for Mannitol in United States?
B BRAUN holds the US marketing authorisation.
What does Mannitol cost in United States?
annual_list: USD 0.00 per year. Final patient cost depends on reimbursement and any patient access scheme.